PMID- 19102401
OWN - NLM
STAT- MEDLINE
DCOM- 20090127
LR  - 20171116
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 55
IP  - 86-87
DP  - 2008 Sep-Oct
TI  - Protein profiling in pancreatic juice for detection of intraductal papillary 
      mucinous neoplasm of the pancreas.
PG  - 1824-9
AB  - BACKGROUND/AIMS: Malignant intraductal papillary mucinous neoplasm of the 
      pancreas (IPMN) has a very poor prognosis, and there is no useful biomarker for 
      an early diagnosis at present. A biomarker is expected to allow an early 
      diagnosis of IPMNs and consequently lead to an improvement of the patients' 
      prognosis. Recent advances in proteomic analysis are remarkable; therefore we 
      explored novel biomarkers for IPMN using Surface-Enhanced Laser Desorption and 
      Ionization (SELDI) Mass Spectrometry. METHODOLOGY: We collected pancreatic juice 
      samples from 33 patients with IPMNs, 54 patients with pancreatic ductal 
      carcinoma, and 31 with chronic pancreatitis. We analyzed the pancreatic juice 
      samples using a SELDI ProteinChip system (Ciphergen Biosystems, Fremont, CA). 
      RESULTS: We identified a 6240-Da peak whose expression in pancreatic juice from 
      patients with IPMNs was significantly higher compared with that in other 
      pancreatic diseases (P<0.01). This 6240-Da protein was partially purified and was 
      identified as pancreatic secretory trypsin inhibitor (PSTI) by amino acid 
      sequencing. The pancreatic juice PSTI levels, as measured by radioimmunoassay, 
      were significantly higher in the IPMN group than in the other groups (P<0.001). 
      When the diagnostic cutoff value of PSTI in pancreatic juice was set at 25000 
      ng/mL, the positive predictive value, negative predictive value, sensitivity, and 
      specificity were respectively 89%, 83%, 48%, and 98%. CONCLUSIONS: PSTI levels of 
      pancreatic juice in patients with IPMN were significantly higher than those in 
      patients with other pancreatic diseases. The PSTI level in pancreatic juice may 
      be useful for the diagnosis of IPMN.
FAU - Shirai, Yoshihiko
AU  - Shirai Y
AD  - Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba 
      University 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. chiba0500@yahoo.co.jp
FAU - Sogawa, Kazuyuki
AU  - Sogawa K
FAU - Yamaguchi, Taketo
AU  - Yamaguchi T
FAU - Sudo, Kentaro
AU  - Sudo K
FAU - Nakagawa, Akihiko
AU  - Nakagawa A
FAU - Sakai, Yuji
AU  - Sakai Y
FAU - Ishihara, Takeshi
AU  - Ishihara T
FAU - Sunaga, Masahiko
AU  - Sunaga M
FAU - Nezu, Masahiko
AU  - Nezu M
FAU - Tomonaga, Takeshi
AU  - Tomonaga T
FAU - Miyazaki, Masaru
AU  - Miyazaki M
FAU - Saisho, Hiromitsu
AU  - Saisho H
FAU - Nomura, Fumio
AU  - Nomura F
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Carrier Proteins)
RN  - 0 (SPINK1 protein, human)
RN  - 50936-63-5 (Trypsin Inhibitor, Kazal Pancreatic)
SB  - IM
MH  - Adenocarcinoma, Mucinous/chemistry/*diagnosis
MH  - Amino Acid Sequence
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Pancreatic Ductal/chemistry/*diagnosis
MH  - Carcinoma, Papillary/chemistry/*diagnosis
MH  - Carrier Proteins/*analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Pancreatic Juice/*chemistry
MH  - Pancreatic Neoplasms/chemistry/*diagnosis
MH  - Protein Array Analysis
MH  - Trypsin Inhibitor, Kazal Pancreatic
EDAT- 2008/12/24 09:00
MHDA- 2009/01/28 09:00
CRDT- 2008/12/24 09:00
PHST- 2008/12/24 09:00 [entrez]
PHST- 2008/12/24 09:00 [pubmed]
PHST- 2009/01/28 09:00 [medline]
PST - ppublish
SO  - Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1824-9.